Wegovy Cost UK: NHS Prescription Charges and Private Treatment Fees

Wegovy (semaglutide 2.4 mg) is a prescription-only GLP-1 receptor agonist licensed by the MHRA for chronic weight management in adults with obesity or overweight with comorbidities. Understanding Wegovy costs is essential for patients considering this treatment, as access and pricing differ substantially between NHS and private routes. NHS availability remains limited, with strict eligibility criteria and regional variation in commissioning. Private treatment represents a significant financial commitment, typically costing £960–£2,700 (price-comparison listing, checked 9 September 2026) annually. This article examines NHS prescription charges, private costs, eligibility requirements, and legitimate ways to access affordable Wegovy treatment whilst highlighting important safety considerations.

What Is Wegovy and How Does It Work?

Wegovy (semaglutide 2.4 mg) is a prescription-only medicine licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) for chronic weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity. It is prescribed as an adjunct to a reduced-calorie diet and increased physical activity. Wegovy belongs to a class of medications called glucagon-like peptide-1 (GLP-1) receptor agonists, originally developed for type 2 diabetes management but now recognised for their significant weight loss effects.

The medication works through several complementary mechanisms. Semaglutide mimics the action of GLP-1, a naturally occurring hormone that regulates appetite and food intake. It binds to GLP-1 receptors in the brain, particularly in areas controlling appetite, leading to reduced hunger and increased feelings of fullness after eating.^[17][3] Additionally, Wegovy slows gastric emptying, meaning food remains in the stomach longer, which contributes to prolonged satiety.^[18][3] These combined effects typically result in reduced caloric intake.

Wegovy is administered as a once-weekly subcutaneous injection using a pre-filled pen device. Treatment begins at a low dose (0.25 mg weekly) and gradually increases over 16-20 weeks to the maintenance dose of 2.4 mg weekly. This titration schedule helps minimise gastrointestinal side effects, which are the most commonly reported adverse reactions, including nausea, vomiting, diarrhoea and constipation. Clinical trials (STEP 1) have demonstrated that Wegovy, when combined with lifestyle interventions including reduced-calorie diet and increased physical activity, can lead to an average weight loss of 10-15% of initial body weight over 68 weeks, though results vary between populations.

Important safety considerations include risks of pancreatitis, gallbladder disease, and dehydration.^[15][3] Wegovy should not be used during pregnancy or breastfeeding, and women of childbearing potential should stop treatment at least 2 months before a planned pregnancy.^[3][14] It should not be used in combination with other GLP-1 receptor agonists.

It is important to note that Wegovy is not a standalone solution but rather one component of a comprehensive weight management programme that should include dietary modification, increased physical activity, and behavioural support.

NHS Wegovy Prescription Costs and Eligibility

Access to Wegovy through the NHS is currently limited and subject to strict eligibility criteria established by the National Institute for Health and Care Excellence (NICE). In March 2023, NICE recommended Wegovy for use within the NHS for specific patient groups, though implementation varies across different integrated care boards (ICBs) due to capacity constraints and local commissioning decisions.^[7][8]

NHS eligibility criteria typically include:

• A body mass index (BMI) of 35 kg/m² or above, or 32.5 kg/m² or above for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family backgrounds

• Some adults with BMI 30-34.9 kg/m² (or lower ethnic-specific thresholds) may be eligible if they meet criteria for specialist weight management services

• At least one weight-related comorbidity such as hypertension, type 2 diabetes, obstructive sleep apnoea, or cardiovascular disease

• Evidence of previous unsuccessful weight management attempts through diet, exercise, and behavioural interventions

• Commitment to participate in an intensive specialist weight management service

Importantly, NICE guidance (TA875) specifies that Wegovy should only be used within a specialist multidisciplinary weight management service and for a maximum of 2 years on the NHS.^[7][8]

For patients who meet NHS eligibility criteria and can access the medication through their local service, Wegovy is provided at the standard NHS prescription charge, which is currently £9.90 per item in England (as of April 2024). Prescriptions are free in Scotland, Wales, and Northern Ireland. Each monthly Wegovy pack is typically dispensed as one prescription item.

The reality is that NHS availability remains limited in many areas. Some regions have waiting lists for specialist weight management services, and some ICBs have not yet fully commissioned Wegovy services. Patients are advised to discuss their eligibility with their GP, who can refer them to specialist weight management services (Tier 3 or 4) where available. It is essential to understand that even if clinically eligible, geographical location may impact actual access to NHS-funded Wegovy treatment.

Private Wegovy Costs in the UK

For patients unable to access Wegovy through the NHS or those who prefer not to wait for NHS services, private prescription represents an alternative route. However, the cost of private Wegovy treatment is substantial and represents a significant financial commitment that patients should carefully consider before commencing therapy.

Private Wegovy costs typically comprise several components. The initial consultation with a private prescriber (GP, specialist, or registered online prescribing service) usually ranges from £79.99–£224.99 (price-comparison listing, checked 9 September 2026). The medication itself costs approximately £79.99–£224.99 per month at maintenance dose (as of early 2024), though starter doses may be slightly less expensive. Prices can vary significantly between providers and may change due to supply constraints. Over a typical 12-month treatment course, patients can expect to spend between £960–£2,700 on medication alone, plus consultation and monitoring costs.

Cost breakdown for private Wegovy treatment:

• Initial consultation and assessment: £79.99–£224.99

• Monthly medication cost (maintenance dose): £79.99–£224.99

• Follow-up consultations (typically every 3 months): £79.99–£224.99 per visit

• Annual total estimated cost: £960–£2,700

Several registered online pharmacies and telehealth services now offer Wegovy prescriptions following remote consultations. Whilst these services may offer convenience and competitive pricing, patients should ensure they are using pharmacies registered with the General Pharmaceutical Council (GPhC) by checking the GPhC online register. Online clinics should be registered with the Care Quality Commission (CQC), and prescribers should be appropriately qualified and registered with the General Medical Council (GMC) or Nursing and Midwifery Council (NMC).

It is crucial to understand that discontinuing Wegovy commonly leads to weight regain, as demonstrated in clinical trials.^[6][16] This means many patients may require ongoing treatment to maintain weight loss. This long-term commitment significantly increases the total cost of private treatment and should be factored into decision-making. Wegovy should not be used in combination with other GLP-1 receptor agonists. Patients should never purchase Wegovy from unregulated sources or websites, as counterfeit medications pose serious health risks.

Ways to Access Affordable Wegovy Treatment

Given the substantial cost of Wegovy, patients seeking more affordable access should explore several legitimate options whilst avoiding potentially dangerous unregulated sources.

Exploring NHS pathways remains the most cost-effective option for eligible patients. Even with waiting lists, patients should request GP referral to specialist weight management services and enquire about their local ICB's commissioning status for Wegovy. Some areas are expanding capacity, and waiting times may vary regionally. Additionally, participating in NHS weight management programmes—even whilst waiting for medication—provides valuable behavioural support and may improve outcomes once treatment begins.

Clinical trials and research studies occasionally offer access to Wegovy or similar medications at no cost. Patients can search the NIHR 'Be Part of Research' website (bepartofresearch.nihr.ac.uk) or discuss research opportunities with their healthcare provider. Whilst trials have specific inclusion criteria and may involve additional monitoring visits, they provide access to specialist care and medication that would otherwise be unaffordable.

Prescription prepayment certificates can reduce costs for patients requiring multiple NHS prescriptions. In England, a 12-month prepayment certificate costs £114.10 (as of April 2024) and covers unlimited prescription items, potentially offering savings for patients on Wegovy alongside other regular medications. This option is only relevant for those with NHS access to Wegovy. Current charges can be checked on the NHS Business Services Authority website.

Employer health schemes and private medical insurance occasionally cover weight management medications, though coverage varies significantly between policies. Patients with private health insurance should review their policy documents or contact their insurer directly to enquire about coverage for obesity medications and associated consultations.

Important safety considerations: Patients should never attempt to reduce costs by sharing pens, using expired medication, or purchasing from unregulated online sources. The rise in Wegovy's popularity has led to a proliferation of counterfeit products that may contain incorrect doses, contaminants, or no active ingredient at all. Always verify that online pharmacies are registered with the GPhC and online clinics with the CQC. Never purchase prescription-only medicines without a legitimate prescription from a qualified healthcare professional.

Seek urgent medical attention for severe abdominal pain (possible pancreatitis), gallbladder symptoms, or persistent vomiting/dehydration. Report suspected side effects via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk). If cost is prohibitive, discuss alternative evidence-based weight management strategies with your GP rather than seeking unsafe alternatives.

Frequently Asked Questions